CervoMed: H2 2024 Data For DLB Program A Major Inflection Point (NASDAQ:CRVO)

Tablet, reading and woman scientist in laboratory working on medical research, project or experiment. Science, career and female researcher with digital technology for pharmaceutical innovation.

Jacob Wackerhausen/iStock via Getty Images

CervoMed (NASDAQ:CRVO) has been enrolling for its phase 2b RewinD-LB study, which is using neflamapimod for the treatment of patients with dementia with Lewy bodies [DLB]. The reason to note this biotech is that it had

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *